ipidacrine | Neuromidine tablets 20 mg, 50 pcs.

Packing

50 pcs.

Pharmacological action of

Neuromidin® has a direct stimulating effect on the conduction of impulse along nerve fibers, interneuronal and neuromuscular synapses of the central nervous system and peripheral nervous system. The pharmacological action of Neuromidin® is based on a combination of two mechanisms of action: blockade of potassium channels of the membrane of neurons and muscle cells, reversible inhibition of cholinesterase in synapses.

Neuromidin® enhances the action on smooth muscles not only of acetylcholine, but also of adrenaline, serotonin, histamine and oxytocin.

Neuromidin® has the following pharmacological effects:

- improves and stimulates the conduction of an impulse in the nervous system and neuromuscular transmission

- enhances contractility of smooth muscle organs under the influence of agonists of acetylcholine, adrenaline, serotonin, histamine and oxytocin receptors, with the exception of potassium chloride

- improves memory, inhibits the progression agent

In preclinical studies, Neuromidin® did not have teratogenic, embryotoxic, mutagenic, carcinogenic and immunotoxic effects, nor did it affect the endocrine system.

Indications

diseases of the peripheral nervous system (mono-and polyneuropathy, polyradiculopathy, myasthenia gravis and myasthenic syndrome of various etiologies)

CNS diseases (bulbar paralysis and paresis recovery period of organic lesions and CNS, cognitive impairment)

intestinal atony (treatment and prevention) (additionally for tablets).

Contraindications

hypersensitivity to any component of the drug

epilepsy

extrapyramidal diseases with hyperkinesis

angina

bradycardia

asthma

mechanical ileus or urinary tract

vestibular disorders

gastric ulcer or duodenal ulcer in the acute stage

pregnancy (drug increases uterine tone)

lactation period

children under 18 years of age (there is no systematic data on application).

Caution: for gastric and duodenal ulcer, thyrotoxicosis, CCC diseases, as well as for patients with a history of obstructive respiratory system diseases or acute respiratory diseases.

Additionally for

tablets Precautions: for lactase deficiency, lactose intolerance, lactose / isomaltose malabsorption syndrome, as the composition of the drug includes lactose.

Special instructions

There are no systematic data on the use of the drug Neuromidin® in children.

Alcohol should be excluded during treatment (enhances the side effects of the drug).

Influence on the ability to drive a car or perform work that requires an increased speed of physical and mental reactions. During treatment, one should refrain from driving a car, as well as engaging in potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.

Composition

Active ingredient - ipidacrine hydrochloride monohydrate - 20 mg (in terms of ipidacrine hydrochloride)

Excipients - lactose, potato starch, calcium stearate.

Dosage and Administration

Inside. Doses and duration of treatment are determined individually depending on the severity of the disease.

Diseases of the peripheral nervous system, myasthenia gravis and myasthenic syndrome: 10-20 mg (0.5-1 tablet) 1-3 times a day. The course of treatment is from one to two months. If necessary, the course of treatment can be repeated several times with a break between courses of 1-2 months.

To prevent myasthenic crises in severe disorders of neuromuscular conduction, 1-2 ml (15-30 mg) of NeuromidinΠ1.5% injection is briefly administered parenterally, then treatment is continued with NeuromidinΠtablets, the dose can be increased to 20-40 mg (1-2 tablets) 5 times a day.

Treatment and prevention of intestinal atony: 20 mg (one tablet) 2-3 times a day for 1-2 weeks.

If the next dose was not taken on time, then it is not additionally taken.

Maximum daily dose of 200 mg.

Side effects

Caused by the excitation of m-cholinergic receptors: salivation, increased sweating, palpitations, nausea, diarrhea, jaundice, bradycardia, epigastric pain, increased secretion of bronchial secretions, bronchospasm, convulsions. Salivation and bradycardia can be reduced with m-anticholinergic drugs (atropine, etc.). Increased uterine tone, skin allergic reactions.

Rarely (after applying higher doses) dizziness, headache, chest pain, vomiting, general weakness, drowsiness, skin reactions (itching, rash) were observed. In these cases, reduce the dose or shortly (1-2 days) interrupt the drug. These side effects are observed in less than 10% of patients.

Drug Interactions

Neuromidine® enhances the sedative effect in combination with central nervous system depressants.

Effects and side effects are enhanced when used together with other cholinesterase inhibitors and m-cholinomimetic agents. In patients with myasthenia gravis, the risk of developing a cholinergic crisis increases if Neuromidin® is used simultaneously with other cholinergic agents.

The risk of developing bradycardia increases if? -adrenoblockers were used prior to treatment with Neuromidin®.

Neuromidin® can be used in combination with nootropic drugs.

Alcohol enhances the side effects of the drug.

Reduces the inhibitory effect on neuromuscular transmission and conduction of local anesthetics, aminoglycosides, potassium chloride along the peripheral nerves.

Overdose

Symptoms: loss of appetite, bronchospasm, lacrimation, increased sweating, narrowing of the pupils, nystagmus, increased gastrointestinal motility, spontaneous bowel movements and urination, vomiting, jaundice, anxiety, conduction, anxiety, disturbances, conduction, disturbance, disturbance, disturbances, conduction, disturbance, disturbance, disturbances, conduction, cardiovascular disease, disturbance, disturbance, disturbance, disturbances , fear, ataxia, convulsions, coma, speech impairment, drowsiness, general weakness.

Treatment: in case of overdose of tablets - gastric lavage. Appointment of m-anticholinergics, including atropine, cyclodol, metacin and other symptomatic therapy.

Storage Conditions

The product should be stored in a dry, dark place at a temperature not exceeding 25 РC.

Form of Treatment

tablets

Olainfarm, Latvia